Abstract
For approximately 50 years the mediator termed slow reacting substance of anaphylaxis (SRS-A) was suspected to play an important role in human allergic reactions, prolonged bronchoconstriction and asthma yet its chemical structure remained elusive (1, 2). Details concerning the biosynthetic origin of this molecule as well as the regulatory mechanisms involved in controlling production and degradation of SRS-A were unknown. In 1979, the structure of SRS-A was elucidated (3) as a family of three novel compounds, having both a lipid portion derived from arachidonic acid and a peptide portion derived from glutathione (4). These molecules are now termed sulfidopeptide leukotrienes (leukotriene C4, D4, E4), which differ in the number of amino acid residues resident in the peptide portion as either gamma-glutamylcysteinylglycine, cysteinylglycine, or cysteine respectively. During the past decade, a great deal of information has been obtained describing the biosynthesis of these molecules, the activation of phospholipase A2 in liberating free arachidonic acid esterified to storage phospholipids (5), the importance of 5-lipoxygenase in generating the reactive intermediate leukotriene A4 (6) and LTC4 synthase which catalyzes the condensation of glutathione with leukotriene A4 yielding LTC4 (7). Furthermore, it is now recognized that sulfidopeptide leukotrienes can be synthesized in a variety of cells including mast cells (8), eosinophils (9), macrophages (10), and basophils (11). Interest in these molecules continues because of the potent biological activities which they possess including bronchoconstriction (12), vasoconstriction (13), and increased vascular permeability (14). Metabolism of LTC4 is known to take place rapidly and includes sequential peptide cleavage reactions (leading to the sulfidopeptide leukotriene described above) as well as ω- and β-oxidation with ultimate elimination of metabolites into the urine (15).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
C. H. Kelloway and E. R. Trethewie, The liberation of a slow-reacting smooth muscle-stimulating substance in anaphylaxis, J. Exptl. Phvsiol. 30: 121 (1940).
R. P. Orange and K. F. Austen, Slow reacting substance of anaphylaxis, Adv. Immunol. 10: 105 (1969).
R. C. Murphy, S. Hammarstrom, and B. Samuelsson, Leukotriene C: A slow reacting substance (SRS) from murine mastocytoma cells, Proc. Natl. Acad. Sci. USA 76: 4275 (1979).
B. Samuelsson, P. Borgeat, S. Hammarstrom, and R. C. Murphy, Leukotrienes: A new group of biologically active compounds, in: “Advances in Prostaglandins and Thromboxane Research,” B. Samuelsson, P. W. Ramwell, and R. Paoletti, eds., Raven Press, New York (1980).
C. C. Leslie, D. R. Voelker, J. Y. Channon, M. W. Wall, and P. T. Zelarney, Properties and purification of an arachidonoyl-hydrolyzing phospholipase A2 from a macrophage cell line, RAW204.7, Biochim. Biophys. Acta 963: 476 (1988).
P. Borgeat and B. Samuelsson, Arachidonic acid metabolism and polymorphonuclear leukocytes: Unstable intermediate in formation of dihydroxy acids, Proc. Natl. Acad. Sci. USA 76: 3213 (1979).
T. Shimizu, Enzymes functional in the synthesis of leukotrienes and related compounds, Int. J. Biochem. 20: 661 (1988).
B. Samuelsson, and C. D. Funk, Enzymes involved in the biosynthesis of leukotriene B4, J. Biol. Chem. 264: 19469 (1989).
A. Jorg, W. R. Henderson, R. C. Murphy, and S. J. Klebanoff, Leukotriene generation by eosinophils, J. Exp. Med. 155: 390 (1982).
C. A. Rouzer, W. A. Scott, A. L. Hamill, and F. A. Cohn, Dynamics of leukotriene C production by macrophages, J. Exp. Med. 152: 1236 (1980).
P. T. Peachell, L. M. Lichtenstein, and R. P. Schleimer, Inhibition by adenosine of histamine and leukotriene release from human basophils, Biochem. Pharm. 38: 1717 (1989).
S. E. Dahlen, P. Hedqvist, S. Hammarstrom, and B. Samuelsson, Leukotrienes are potent constrictors of human bronchi, Nature 288: 484 (1980).
N. A. Soter, R. A. Lewis, E. J. Corey, and K. F. Austen, Local effects of synthetic leukotrienes (LTC4, LTD4, LTE4, and LTB4) in human skin, J. Invest. Dermatol. 80: 115 (1983).
Z. Marom, J. H. Shelhamer, M. K. Bach, D. R. Morton, and M. Kaliner, Slow reacting substances LTC4 and D4 increase the release of mucus from human airways in vitro, Am. Rev. Respir. Dis. 126: 449 (1982).
A. Sala, N. Voelkel, J. Maclouf, and R. C. Murphy, LTE4 elimination and metabolism in normal human subjects, J. Biol. Chem. 265: 21771 (1990).
C. P. Page, Platelets as inflammatory cell, Immunopharmacol. 17: 51 (1989).
P. M. Henson, Interactions between neutrophils and platelets, Editorial, Lab. Invest. 62: 391 (1990).
J. Wester, J. J. Sixma, J. J. Geuze, and H. J. G. Heijin, Morphology of the hemostatic plug in human skin wounds. Transformation of the healing, Lab. Invest. 41: 182 (1979).
P. M. Henson and C. G. Cochrane, Immunological induction of increased vascular permeability. I. A rabbit passive cutaneous anaphylactic reaction requiring complement, platelets and neutrophils, J. Exp. Med. 129: 153 (1969).
P. M. Henson, Mechanisms of release of constituents from rabbit platelets by antigen-antibody complexes and complement II. Interaction of platelets with neutrophils, J. Immunol. 105: 490 (1970).
A. Del Maschio, V. Evangelista, G. Rajtar, Z.-M. Chen, C. Cerletti, and G. De Gaetano, Platelet activation by polymorphonuclear leukocytes exposed to chemotactic agents, Am. J. Phvsiol. 258: H870 (1990).
M. A. Selak, M. Chignard, and J. B. Smith, Cathepsin G is a strong platelet agonist released by neutrophils, Biochem. J. 251: 293 (1988).
D. Y. Tzeng, T. F. Deuel, J. S. Huang, R. M. Senior, L. A. Boxer, and R. L. Baehner, Platelet-derived growth factor promotes polymorphonuclear leukocyte activation, Blood 64: 1123 (1984).
S. T. McGarrity, T. M. Hyers, and R. O. Webster, Inhibition of neutrophil functions by platelets and platelet-derived products: Description of multiple inhibitory properties, J. Leuk. Biol. 44: 93 (1988).
S. M. Albelda and C. A. Buck, Integrins and other cell adhesion molecules, FASEB J. 4: 2868–2880 (1990).
T. A. Springer, Adhesion receptors of the immune system, Nature 346: 425 (1990).
T. A. Springer and L. A. Lasky, Sticky sugars for selectins, Nature 349: 196 (1991).
E. Larsen, A. Celi, G. E. Gilbert, B. C. Furie, J. K. Erban, R. Bonfanti, D. D. Wagner, and B. Furie, PADGEM protein: a receptor that mediates the interaction of activated platelets with neutrophils and monocytes, Cell 59: 305 (1989).
L. Corral, M. S. Singer, B. A. Macher, and S. D. Rosen, Requirement for sialic acid on neutrophils in a GMP-140 (PADGEM) mediated adhesive interaction with activated platelets, Biochem. Biophys. Res. Commun. 172: 1349 (1990).
S. A. Hamburger and R. P. McEver, GMP-140 mediates adhesion of stimulated platelets to neutrophils, Blood 75: 550 (1990).
J. Maclouf, B. Fruteau de Laclos, and P. Borgeat, Stimulation of leukotriene biosynthesis in human blood leukocytes by platelet-derived 12-hydroxyperoxy-eicosatetraenoic acids, Proc. Natl. Acad. Sci. USA 79: 6042 (1982).
A. J. Marcus, L. B. Safier, H. L. Ullman, N. Islam, M. J. Broekman, N. Islam, T. D. Oglesby, and R. R. Gorman, 12S,20-Dihydroxyicosatetraenoic acid: A new eicosanoid synthesized by neutrophils from 12S-hydroxyicosatetraenoic acid produced by thrombin-or collagen-stimulated platelets, Proc. Natl. Acad. Sci. USA 81: 903 (1984).
P. Wong, Y. K. Westlund, M. Hamberg, E. Granstrom, P. H. W. Chao, and B. Samuelsson, ω-Hydroxylation of 12-L-hydroxy-5, 8, 10, 14-eicosatetraenoic acid in human polymorphonuclear leukocytes, J. Biol. Chem. 259: 2683 (1984).
A. J. Marcus, L. B. Safier, H. L. Ullman, N. Islam, M. J. Broekman, J. R. Falck, S. Fischer, and C. von Schacky, Platelet-neutrophil interactions: (12S)-hydroxy-eicosatetraen-l, 20-dioic acid: A new eicosanoid synthesized by unstimulated neutrophils from (12S)-20-dihydroxyeicosatetraenoic acid, J. Biol. Chem. 263: 2223 (1988).
P. Borgeat, M. Hamberg, and B. Samuelsson, Transformation of arachidonic acid in dihomo-7-linolenic acid by rabbit PMN leukocytes, J. Biol. Chem. 251: 7816 (1976).
P. Borgeat and B. Samuelsson, Transformation of arachidonic acid by rabbit polymorphonuclear leukocytes, J. Biol. Chem. 254: 2643 (1979).
T. Shimizu, O. Radmar, and B. Samuelsson, Enzyme with dual lipoxygenase activities catalyze leukotriene A4 synthesis from arachidonic acid, Proc. Natl. Acad. Sci. USA 81: 689 (1984).
R. A. F. Dixon, R. E. Diehl, E. Opas, E. Rands, P. J. Vickers, J. F. Evans, J. W. Gillard, and D. K. Miller, Requirement of a 5-lipoxygenase-activating protein for leukotriene synthesis, Nature 343: 282 (1990).
C. A. Rouzer and S. Kargman, Translocation of 5-lipoxygenase to the membrane in human leukocytes challenged with ionophore A23187, J. Biol. Chem. 263: 10980 (1988).
C. A. Dahinden, R. M. Clancy, M. Gross, J. M. Chiller, and T. E. Hugli, Leukotriene C4 production by murine mast cells: Evidence of a role for extracellular leukotriene A4, Proc. Natl. Acad. Sci. USA 82: 6632 (1985).
F. A. Fitzpatrick, D. R. Morton, and M. A. Wynalda, Albumin stabilizes leukotriene A4, J. Biol. Chem. 257: 4680 (1982).
B. K. Lam, W. F. Owen, K. F. Austen, and R. J. Soberman, The identification of a distinct export step following the biosynthesis of leukotriene C4 by human eosinophils, J. Biol. Chem. 264: 12885 (1989).
B. K. Lam, W. F. Owen, K. F. Austen, and R. J. Soberman, The mechanism of leukotriene B4 export from human polymorphonuclear leukocytes, J. Biol. Chem. 265: 13438 (1990).
J. Maclouf and R. C. Murphy, Transcellular metabolism of neutrophil-derived leukotriene A4 by human platelets, J. Biol. Chem. 263: 174 (1988).
H. E. Claesson and J. Haeggstrom, Human endothelial cells stimulate leukotriene synthesis and convert granulocyte released leukotriene A4 into leukotrienes B4, C4, D4, and E4, Eur. J. Biochem. 173: 93 (1988).
C. Edenius, K. Heidvall, and J.A. Lindgren, Novel transformation of granulocyte-derived leukotriene A4 into cysteinyl-containing leukotrienes by human platelets, Eur. J. Biochem. 178: 81 (1988).
J. Maclouf, R. C. Murphy, and P. M. Henson, Transcellular sulfidopeptide leukotriene biosynthetic capacity of vascular cells, Blood 74: 703 (1989).
J. Maclouf, R. C. Murphy, and P. M. Henson, Transcellular biosynthesis of sulfidopeptide leukotrienes during receptor-mediated stimulation of human neutrophil/platelet mixtures, Blood 76: 1838 (1990).
A. Fradin, J. A. Zirrolli, J. Maclouf, L. Vausbinder, P. M. Henson, and R. C. Murphy, PAF and leukotriene biosynthesis in whole blood: A model for the study of transcellular arachidonate metabolism, J. Immunol. 143: 3680 (1989).
R. A. Lewis, and K. F. Austen, The biologically active leukotrienes. Biosynthesis, metabolism, receptors, functions, and pharmacology, J. Clin. Invest. 73: 889 (1984).
A. J. Marcus, Thrombosis and inflammation as multicellular processes: Pathophysiological significance of transcellular metabolism, Blood 76: 1903 (1990).
R. C. Murphy and P. M. Henson, Mediator network, in: “Annales de l’Institut Pasteur/Immunologie,” Institut Pasteur, ed., Institut Pasteur (1985).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1991 Plenum Press, New York
About this chapter
Cite this chapter
Murphy, R.C., Maclouf, J., Henson, P.M. (1991). Interaction of Platelets and Neutrophils in the Generation of Sulfidopeptide Leukotrienes. In: Wong, P.YK., Serhan, C.N. (eds) Cell-Cell Interactions in the Release of Inflammatory Mediators. Advances in Experimental Medicine and Biology, vol 314. Springer, Boston, MA. https://doi.org/10.1007/978-1-4684-6024-7_5
Download citation
DOI: https://doi.org/10.1007/978-1-4684-6024-7_5
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4684-6026-1
Online ISBN: 978-1-4684-6024-7
eBook Packages: Springer Book Archive